Regeneron Pharmaceuticals has entered a strategic immuno-oncology collaboration with Netherlands-based ISA Pharmaceuticals to advance ISA101 therapy in combination with cemiplimab (REGN2810).

Based on the oncogenic antigens delivery in the form of synthetic long peptides, ISA101 targets cancer induced by human papillomavirus type 16 (HPV16).

Cemiplimab is a programmed cell death protein 1 (PD-1) antibody formulated with Regeneron’s VelocImmune technology that is designed to generate optimised fully human antibodies.

The drug is being developed by Regeneron under a global collaboration agreement with Sanofi.

Regeneron Clinical Sciences vice-president Israel Lowy said: “Regeneron continues to expand and advance our immuno-oncology programme by studying multiple combination therapies in order to fully explore the scientific possibilities in this relatively new field.

“We’re eager to investigate the impact of adding cemiplimab with the goal of further enabling the body’s immune system to attack the cancer.”

“Early clinical results with ISA101 in HPV16-positive indications have been promising, and we’re eager to investigate the impact of adding cemiplimab with the goal of further enabling the body’s immune system to attack the cancer.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Regeneron and ISA are set to jointly sponsor and perform clinical trials for the combination of ISA101 and cemiplimab to treat patients with cervical, and head and neck cancers.

The firms will share clinical trial costs and exchange product supply, while Regeneron has agreed to offer an upfront payment for an option to ISA101’s exclusive global licence.

ISA Pharmaceuticals CEO Ronald Loggers said: “This collaboration with Regeneron is a strong validation of our proprietary synthetic long peptides (SLP) platform and know-how.”